BIO3D Stock Overview
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €32.00 |
| 52 Week High | €35.50 |
| 52 Week Low | €32.00 |
| Beta | 0.29 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 60.00% |
| 5 Year Change | 31.96% |
| Change since IPO | 118.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO3D | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 1.4% |
| 1Y | n/a | -27.7% | 1.1% |
Return vs Industry: Insufficient data to determine how BIO3D performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BIO3D performed against the UK Market.
Price Volatility
| BIO3D volatility | |
|---|---|
| BIO3D Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BIO3D has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIO3D's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,228 | Michael Ramroth | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO3D fundamental statistics | |
|---|---|
| Market cap | €1.46b |
| Earnings (TTM) | -€47.20m |
| Revenue (TTM) | €517.40m |
2.4x
P/S Ratio-26.3x
P/E RatioIs BIO3D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO3D income statement (TTM) | |
|---|---|
| Revenue | €517.40m |
| Cost of Revenue | €394.00m |
| Gross Profit | €123.40m |
| Other Expenses | €170.60m |
| Earnings | -€47.20m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 10, 2023
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 23.85% |
| Net Profit Margin | -9.12% |
| Debt/Equity Ratio | 185.4% |
How did BIO3D perform over the long term?
See historical performance and comparison